Compare ACIU & CXDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACIU | CXDO |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.9M | 223.1M |
| IPO Year | 2015 | 1999 |
| Metric | ACIU | CXDO |
|---|---|---|
| Price | $2.36 | $6.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $10.00 | $9.20 |
| AVG Volume (30 Days) | 171.9K | ★ 484.4K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 166.67 |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $68,167,000.00 |
| Revenue This Year | $706.75 | $45.26 |
| Revenue Next Year | $321.13 | $13.31 |
| P/E Ratio | ★ N/A | $129.80 |
| Revenue Growth | N/A | ★ 12.05 |
| 52 Week Low | $2.03 | $5.55 |
| 52 Week High | $4.00 | $11.23 |
| Indicator | ACIU | CXDO |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 38.29 |
| Support Level | $2.13 | $5.81 |
| Resistance Level | $2.41 | $7.02 |
| Average True Range (ATR) | 0.11 | 0.44 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 65.31 | 29.72 |
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.